Cover Image
市場調查報告書

再生醫療的全球市場預測 2021年:細胞療法、遺傳基因療法、人體組織工程、免疫療法

Regenerative Medicines Market by Therapy (Cell Therapy, Gene Therapy, Immunotherapy, Tissue Engineering), Product (Cell-Based, Acellular), Application, Region - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 363089
出版日期 內容資訊 英文 160 Pages
訂單完成後即時交付
價格
Back to Top
再生醫療的全球市場預測 2021年:細胞療法、遺傳基因療法、人體組織工程、免疫療法 Regenerative Medicines Market by Therapy (Cell Therapy, Gene Therapy, Immunotherapy, Tissue Engineering), Product (Cell-Based, Acellular), Application, Region - Global Forecast to 2021
出版日期: 2016年07月07日 內容資訊: 英文 160 Pages
簡介

全球再生醫療的市場規模,預計從2016年到2021年以23.7%的年複合成長率擴大,從2016年的170億6000萬美元,到2021年達到494億1,000萬美元。該市場的高成長,是由多樣的產品、技術及器官移植需求的劇增所帶來。

本報告提供全球再生醫療市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 再生醫療市場上收成好的機會

第5章 再生醫療的全球市場:概要

  • 簡介
  • 市場區隔
    • 各治療法
    • 各產品
    • 各應用領域
  • 市場動態
  • 促進要素
    • 支援政府、民間資金再生醫療產品的開發
    • 全球醫療費的增加
    • 老年人口的增加
  • 抑制因素
    • 對再生醫療的嚴格法規核准流程
    • 由於研究開發 (R&D) 使用胚胎幹細胞造成的倫理性問題
  • 機會
    • 器官移植需求的增加
    • 促進市場的強力產品平台
    • R&D支出的增加
  • 課題
    • 缺乏清楚的法規指南
    • 幹細胞加工產生的高成本

第6章 再生醫療的全球市場:各產品

  • 簡介
  • 細胞為基礎的產品
    • 自我細胞為基礎的產品
    • 同種異體細胞為基礎的產品
  • 無細胞產品

第7章 再生醫療的全球市場:各治療法

  • 簡介
  • 細胞療法
  • 遺傳基因療法
  • 人組織工程
  • 免疫療法

第8章 再生醫療的全球市場:各應用領域

  • 簡介
  • 整形外科、肌肉骨骼系統脊椎
  • 皮膚科
  • 心血管
  • 中樞神經系統
  • 癌症
  • 糖尿病
  • 其他

第9章 再生醫療的全球市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲 (RoE)
  • 亞太地區
  • 其他 (RoW)

第10章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢

第11章 企業簡介

  • 簡介
  • VERTEX PHARMACEUTICALS INCORPORATED
  • CELGENE CORPORATION
  • ACELITY (KCI LICENSING)
  • NUVASIVE, INC.
  • ORGANOGENESIS INC.
  • JAPAN TISSUE ENGINEERING CO., LTD (SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
  • VERICEL CORPORATION
  • CYTORI THERAPEUTICS INC.
  • STEMCELLS, INC.
  • ADVANTAGENE, INC.
  • MESOBLAST LTD

第12章 附錄

目錄
Product Code: BT 4419

The global regenerative medicines market is expected to reach USD 49.41 billion by 2021 from USD 17.06 billion in 2016, at a CAGR of 23.7% during the period of 2016-2021. The global regenerative medicines market is segmented based on product, application, therapy, and region. The cell-based product segment is expected to register the highest growth rate in the regenerative medicines market, by product, during the forecast period. The high growth in this segment is attributed to the variety of products and technologies and rapid increase in the demand of organ transplantation due to which they are most preferred in various applications.

Based on therapy, the regenerative medicines market is segmented into cell therapy, gene therapy, immunotherapy, and tissue engineering. The cell therapy segment is expected to account for the largest share of the market in 2016. Increasing funding from various governments and private organizations for carrying out research and development activities related to various cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness regarding the benefits of stem cell therapies will drive the growth of this segment.

By application, the segments are orthopaedic & musculoskeletal spine, dermatology, CNS, cardiovascular, oncology, diabetes, and others where cardiovascular and oncology segments are growing rapidly owing to the increasing cases of cancers and cardiovascular diseases especially in the U.S. Over 60,000 stem cell transplants are performed annually globally for the treatment of oncology.

Geographically, the regenerative medicines market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by rising incidences of cancer, increasing government support, expanding biopharmaceutical industry, and launch of new products in the market.

The major factors contributing to the growth of the regenerative medicines market include rising regulatory approvals for cell culture-based products, increasing funding for cell-based research, and technological advancements. On the other hand, high cost of research and lack of infrastructure, especially in emerging economies, are the major factors restraining the growth of this market.

The major players in this market include Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Corning Incorporated (U.S.), Organogenesis Inc. (U.S.), Acelity (KCI Licensing) (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), among others.

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the regenerative medicines market.
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the regenerative medicines market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the regenerative medicines market
  • Market Development: Comprehensive information about emerging markets.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the regenerative medicines market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY & PRICING
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. LUCRATIVE OPPORTUNITIES IN THE REGENERATIVE MEDICINES MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. REGENERATIVE MEDICINES MARKET SEGMENTATION, BY THERAPY
    • 5.2.2. REGENERATIVE MEDICINES MARKET SEGMENTATION, BY PRODUCT
    • 5.2.3. REGENERATIVE MEDICINES MARKET SEGMENTATION, BY APPLICATION
  • 5.3. MARKET DYNAMICS
  • 5.4. DRIVERS
    • 5.4.1. GOVERNMENT AND PRIVATE FUNDING TO SUPPORT THE DEVELOPMENT OF REGENERATIVE MEDICINES PRODUCTS
    • 5.4.2. INCREASE IN GLOBAL HEALTHCARE EXPENDITURE
    • 5.4.3. INCREASE IN AGING POPULATION
  • 5.5. RESTRAINTS
    • 5.5.1. STRINGENT REGULATORY APPROVAL PROCESS FOR REGENERATIVE MEDICINES
    • 5.5.2. ETHICAL ISSUES WITH THE USE OF EMBRYONIC STEM CELL FOR RESEARCH AND DEVELOPMENT
  • 5.6. OPPORTUNITIES
    • 5.6.1. RISING DEMAND FOR ORGAN TRANSPLANTATION
    • 5.6.2. STRONG PRODUCT PIPELINE TO DRIVE THE MARKET
    • 5.6.3. INCREASE IN R&D SPENDING
  • 5.7. CHALLENGES
    • 5.7.1. LACK OF CLEAR REGULATORY GUIDELINES
    • 5.7.2. HIGH COSTS INCURRED IN STEM CELL PROCESSING

6. GLOBAL REGENERATIVE MEDICINES MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. CELL-BASED PRODUCTS
    • 6.2.1. AUTOLOGOUS CELL-BASED PRODUCTS
    • 6.2.2. ALLOGENEIC CELL-BASED PRODUCTS
  • 6.3. ACELLULAR PRODUCTS

7. GLOBAL REGENERATIVE MEDICINES MARKET, BY THERAPY

  • 7.1. INTRODUCTION
  • 7.2. CELL THERAPY
  • 7.3. GENE THERAPY
  • 7.4. TISSUE ENGINEERING
  • 7.5. IMMUNOTHERAPY

8. REGENERATIVE MEDICINES MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. ORTHOPEDIC & MUSCULOSKELETAL SPINE
  • 8.3. DERMATOLOGY
  • 8.4. CARDIOVASCULAR
  • 8.5. CENTRAL NERVOUS SYSTEM
  • 8.6. ONCOLOGY
  • 8.7. DIABETES
  • 8.8. OTHERS

9. GLOBAL REGENERATIVE MEDICINES MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. U.S.
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. UK
    • 9.3.3. FRANCE
    • 9.3.4. ITALY
    • 9.3.5. SPAIN
    • 9.3.6. REST OF EUROPE (ROE)
  • 9.4. ASIA-PACIFIC
  • 9.5. REST OF THE WORLD (ROW)

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. COMPETITIVE SITUATION AND TRENDS
    • 10.3.1. NEW PRODUCT LAUNCHES
    • 10.3.2. ACQUISITIONS
    • 10.3.3. REGULATORY APPROVALS
    • 10.3.4. PARTNERSHIPS

11. COMPANY PROFILE (Overview, Financial*, Products & Services, Strategy, and Developments)

  • 11.1. INTRODUCTION
  • 11.2. VERTEX PHARMACEUTICALS INCORPORATED
  • 11.3. CELGENE CORPORATION
  • 11.4. ACELITY (KCI LICENSING)
  • 11.5. NUVASIVE, INC.
  • 11.6. ORGANOGENESIS INC.
  • 11.7. JAPAN TISSUE ENGINEERING CO., LTD (SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
  • 11.8. VERICEL CORPORATION
  • 11.9. CYTORI THERAPEUTICS INC.
  • 11.10. STEMCELLS, INC.
  • 11.11. ADVANTAGENE, INC.
  • 11.12. MESOBLAST LTD

*Details might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.5. AVAILABLE CUSTOMIZATIONS
  • 12.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: GLOBAL REGENERATIVE MEDICINES MARKET SIZE, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 2: CELL-BASED REGENERATIVE MEDICINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 3: CELL-BASED REGENERATIVE MEDICINES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 4: AUTOLOGOUS REGENERATIVE MEDICINES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 5: ALLOGENEIC REGENERATIVE MEDICINES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 6: ACELLULAR REGENERATIVE MEDICINES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 7: GLOBAL REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 8: CELL THERAPY MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 9: GENE THERAPY MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 10: TISSUE ENGINEERING MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 11: IMMUNOTHERAPY MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 12: REGENERATIVE MEDICINES MARKET SIZE, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 13: ORTHOPEDIC & MUSCULOSKELETAL SPINE MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 14: DERMATOLOGY MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 15: CARDIOVASCULAR MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 16: CENTRAL NERVOUS SYSTEM MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 17: ONCOLOGY MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 18: DIABETES MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 19: OTHERS MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 20: GLOBAL REGENERATIVE MEDICINES MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 21: NORTH AMERICA REGENERATIVE MEDICINES MARKET, BY GEOGRAPHY, 2014-2021 (USD BILLION)
  • TABLE 22: NORTH AMERICA REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 23: NORTH AMERICA CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 24: NORTH AMERICA REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 25: NORTH AMERICA REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 26: U.S. REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 27: U.S. CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 28: U.S. REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 29: U.S. REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 30: CANADA REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 31: CANADA CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 32: CANADA REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 33: CANADA REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 34: EUROPE REGENERATIVE MEDICINES MARKET, BY GEOGRAPHY, 2014-2021 (USD BILLION)
  • TABLE 35: EUROPE REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 36: EUROPE CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 37: EUROPE REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 38: EUROPE REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 39: GERMANY REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 40: GERMANY CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 41: GERMANY REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 42: GERMANY REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 43: UK REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 44: UK CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 45: UK REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 46: UK REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 47: FRANCE REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 48: FRANCE CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 49: FRANCE REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 50: FRANCE REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 51: ITALY REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 52: ITALY CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 53: ITALY REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 54: ITALY REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 55: SPAIN REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 56: SPAIN CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 57: SPAIN REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 58: SPAIN REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 59: REST OF EUROPE(ROE) REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 60: REST OF EUROPE(ROE) CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 61: REST OF EUROPE (ROE) REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 62: REST OF EUROPE (ROE) REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 63: ASIA-PACIFIC REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 64: ASIA-PACIFIC CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 65: ASIA-PACIFIC REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 66: ASIA-PACIFIC REGENERATIVE MEDICINES MARKET, BY THERAPY, 2013-2021 (USD BILLION)
  • TABLE 67: ROW REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014-2021 (USD BILLION)
  • TABLE 68: ROW CELL-BASED PRODUCTS MARKET, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 69: ROW REGENERATIVE MEDICINES MARKET, BY APPLICATION, 2014-2021 (USD BILLION)
  • TABLE 70: ROW REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014-2021 (USD BILLION)
  • TABLE 71: NEW PRODUCT LAUNCHES, 2013-2016
  • TABLE 72: ACQUISITIONS, 2014-2016
  • TABLE 73: REGULATORY APPROVALS, 2013-2016
  • TABLE 74: PARTNERSHIPS, 2016
  • TABLE 75: AGREEMENTS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: REGENERATIVE MEDICINES MARKET, BY PRODUCT (2016 VS. 2021)
  • FIGURE 7: REGENERATIVE MEDICINES MARKET, BY THERAPY, 2016 VS. 2021
  • FIGURE 8: ORTHOPEDIC & MUSCULOSKELETAL SPINE FORM THE LARGEST APPLICATION SEGMENT
  • FIGURE 9: GLOBAL REGENERATIVE MEDICINES MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
  • FIGURE 10: CELL THERAPY SEGMENT DOMINATES THE REGENERATIVE MEDICINES MARKET
  • FIGURE 11: ASIA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 12: REGENERATIVE MEDICINES MARKET SEGMENTATION
  • FIGURE 13: REGENERATIVE MEDICINES MARKET SEGMENTATION, BY THERAPY
  • FIGURE 14: REGENERATIVE MEDICINES MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 15: REGENERATIVE MEDICINES MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 16: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: GLOBAL REGENERATIVE MEDICINES MARKET, BY PRODUCT
  • FIGURE 18: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GLOBAL REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 19: CELL-BASED PRODUCTS, BY TYPE
  • FIGURE 20: ALLOGENEIC SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE CELL-BASED REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 21: NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CELL-BASED REGENERATIVE MEDICINES MARKET IN 2016
  • FIGURE 22: NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE AUTOLOGOUS REGENERATIVE MEDICINES MARKET IN 2016
  • FIGURE 23: NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF ALLOGENEIC REGENERATIVE MEDICINES MARKET IN 2016
  • FIGURE 24: ASIA-PACIFIC EXPECTED TO BE THE FASTEST-GROWING SEGMENT OF THE ACELLULAR REGENERATIVE MEDICINES MARKET DURING THE FORECAST PERIOD
  • FIGURE 25: GLOBAL REGENERATIVE MEDICINES MARKET, BY THERAPY
  • FIGURE 26: THE CELL THERAPY SEGMENT TO LEAD THE GLOBAL REGENERATIVE MEDICINES MARKET DURING THE FORECAST PERIOD
  • FIGURE 27: CELL THERAPY MARKET, BY REGION, 2016 & 2021 (USD BILLION)
  • FIGURE 28: GENE THERAPY MARKET, BY REGION, 2016 & 2021 (USD BILLION)
  • FIGURE 29: TISSUE ENGINEERING MARKET, BY REGION, 2016 & 2021 (USD BILLION)
  • FIGURE 30: IMMUNOTHERAPY MARKET, BY REGION, 2016 & 2021 (USD BILLION)
  • FIGURE 31: REGENERATIVE MEDICINES MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 32: ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT DOMINATED THE REGENERATIVE MEDICINE APPLICATION MARKET IN 2015
  • FIGURE 33: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE GLOBAL REGENERATIVE MEDICINES MARKET FOR ORTHOPEDIC & MUSCULOSKELETAL SPINE IN 2015
  • FIGURE 34: NORTH AMERICA DOMINATED THE REGENERATIVE MEDICINES MARKET FOR DERMATOLOGY IN 2015
  • FIGURE 35: ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL REGENERATIVE MEDICINES MARKET FOR CARDIOVASCULAR APPLICATIONS
  • FIGURE 36: NORTH AMERICA DOMINATED THE REGENERATIVE MEDICINES MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS IN 2015
  • FIGURE 37: ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL REGENERATIVE MEDICINES MARKET FOR ONCOLOGY APPLICATION
  • FIGURE 38: ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL REGENERATIVE MEDICINES MARKET FOR DIABETES APPLICATION
  • FIGURE 39: NORTH AMERICA DOMINATED THE REGENERATIVE MEDICINES MARKET FOR OTHER APPLICATIONS IN 2015
  • FIGURE 40: REGIONAL SNAPSHOT (2015)
  • FIGURE 41: THE REGENERATIVE MEDICINES MARKET IN THE ASIA-PACIFIC REGION IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 42: NORTH AMERICA REGENERATIVE MEDICINES MARKET SNAPSHOT
  • FIGURE 43: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICA REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 44: ORTHOPEDIC & MUSCULOSKELETAL SPINE APPLICATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICA REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 45: CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICA REGENERATIVE MEDICINES THERAPY MARKET IN 2015
  • FIGURE 46: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE U.S. REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 47: ORTHOPEDIC & MUSCULOSKELETAL SPINE APPLICATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE U.S. REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 48: CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE U.S. REGENERATIVE MEDICINES THERAPY MARKET
  • FIGURE 49: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE CANADA REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 50: ORTHOPEDIC & MUSCULOSKELETAL SPINE APPLICATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE CANADA REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 51: CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE CANADA REGENERATIVE MEDICINES THERAPY MARKET
  • FIGURE 52: EUROPE REGENERATIVE MEDICINES MARKET SNAPSHOT
  • FIGURE 53: AMONG PRODUCTS, THE CELL-BASED PRODUCTS SEGMENT LED THE EUROPE REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 54: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE EUROPE REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 55: THE CELL THERAPY SEGMENT LED THE EUROPE REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 56: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GERMANY REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 57: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE GERMANY REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 58: THE CELL THERAPY SEGMENT LED THE GERMANY REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 59: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE U.K. REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 60: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE UK REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 61: THE CELL THERAPY SEGMENT LED THE UK REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 62: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE FRANCE REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 63: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE FRANCE REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 64: THE CELL THERAPY SEGMENT LED THE FRANCE REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 65: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ITALY REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 66: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ITALY REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 67: THE CELL THERAPY SEGMENT LED THE ITALY REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 68: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE SPAIN REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 69: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE SPAIN REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 70: THE CELL THERAPY SEGMENT LED THE SPAIN REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 71: CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE REST OF THE EUROPE (ROE) REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 72: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE REST OF EUROPE (ROE) REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 73: THE CELL THERAPY SEGMENT LED THE REST OF EUROPE (ROE) REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 74: ASIA-PACIFIC REGENERATIVE MEDICINES MARKET SNAPSHOT
  • FIGURE 75: AMONG PRODUCTS, THE CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ASIA-PACIFIC REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 76: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ASIA-PACIFIC REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 77: THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ASIA-PACIFIC REGENERATIVE MEDICINES IN 2015
  • FIGURE 78: THE CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ROW REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 79: AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ROW REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 80: THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ROW REGENERATIVE MEDICINES MARKET IN 2015
  • FIGURE 81: LEADING MARKET PLAYERS ADOPTED BOTH ORGANIC AND INORGANIC GROWTH STRATEGIES OVER THE LAST FOUR YEARS (2013-2016)
  • FIGURE 82: GLOBAL REGENERATIVE MEDICINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 83: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES & PRODUCT ENHANCEMENTS IS THE KEY STRATEGY
  • FIGURE 84: GEOGRAPHIC REVENUE SNAPSHOT (2015)
  • FIGURE 85: VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT
  • FIGURE 86: CELGENE CORPORATION: COMPANY SNAPSHOT
  • FIGURE 87: ACELITY (KCI LICENSING): COMPANY SNAPSHOT
  • FIGURE 88: NUVASIVE, INC.: COMPANY SNAPSHOT
  • FIGURE 89: VERICEL CORPORATION: COMPANY SNAPSHOT
  • FIGURE 90: CYTORI THERAPEUTICS INC.: COMPANY SNAPSHOT
  • FIGURE 91: STEMCELLS, INC.: COMPANY SNAPSHOT
Back to Top